We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Amphion Innovations Plc | LSE:AMP | London | Ordinary Share | GB00B0DJNP99 | ORD 1P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 0.15 | 0.00 | 01:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| 0 | 0 | N/A | 0 |
TIDMAMP
Amphion Innovations PLC
23 August 2018
Amphion Innovations plc
("Amphion" or "the Company")
Polarean Update
London and New York, 23 August 2018 - Amphion Innovations plc (AIM: AMP), the developer of medical, life science, and technology businesses, notes that its partner company Polarean Imaging plc ("Polarean") has announced that the first patient has been enrolled in its Phase III FDA clinical trial which aims to demonstrate non-inferiority of the Company's drug-device combination, using hyperpolarised 129-Xenon (129Xe) gas MRI, against an approved comparator.
This news means that Polarean is now in the process of its Phase III clinical trial. Polarean is listed on the AIM market of the London Stock Exchange under the ticker POLX.
Amphion currently holds c. 17 million shares, equivalent to 21.7% of the enlarged Share Capital of Polarean.
For further information please contact:
Amphion Innovations Tel: +1 (212) 210 6224 Charlie Morgan Panmure Gordon Limited (Nominated Adviser Tel: +44 (0)20 and Corporate Broker) 7886 2500 Freddy Crossley / Ryan McCarthy / Emma Earl (Corporate Finance) Charlie Leigh-Pemberton (Corporate Broking) Northland Capital Partners Limited (Joint Tel: +44 (0)20 3861 Corporate Broker) 6625 David Hignell (Corporate Finance) Vadim Alexandre (Corporate Broking) Walbrook PR Tel: +44 (0)20 7933 8780 or Anna Dunphy / Paul McManus amphion@walbrookpr.com
About Amphion Innovations plc - www.amphionplc.com
Amphion Innovations is a developer of medical, life science and technology businesses. We use our extensive experience in company building to invest and build shareholder value in high growth companies in the US and UK. Amphion has significant shareholding in a small number of Partner Companies developing proven technologies targeting substantial commercial marketplaces. The Amphion model has been refined to optimise the commercialisation of patents and other intellectual property within the Partner Companies.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
END
NRALLFLSTTIVFIT
(END) Dow Jones Newswires
August 23, 2018 10:20 ET (14:20 GMT)
1 Year Amphion Innovations Chart |
1 Month Amphion Innovations Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
